PMC:7102591 / 20012-21015 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"595","span":{"begin":207,"end":212},"obj":"Gene"},{"id":"596","span":{"begin":235,"end":239},"obj":"Gene"},{"id":"597","span":{"begin":505,"end":508},"obj":"Gene"},{"id":"598","span":{"begin":835,"end":839},"obj":"Gene"},{"id":"599","span":{"begin":666,"end":669},"obj":"Gene"},{"id":"600","span":{"begin":344,"end":352},"obj":"Species"},{"id":"601","span":{"begin":301,"end":305},"obj":"Disease"},{"id":"602","span":{"begin":396,"end":405},"obj":"Disease"},{"id":"603","span":{"begin":618,"end":622},"obj":"Disease"},{"id":"604","span":{"begin":641,"end":665},"obj":"Disease"},{"id":"605","span":{"begin":750,"end":765},"obj":"Disease"},{"id":"606","span":{"begin":866,"end":871},"obj":"Disease"},{"id":"607","span":{"begin":916,"end":931},"obj":"Disease"},{"id":"608","span":{"begin":942,"end":951},"obj":"Disease"},{"id":"609","span":{"begin":987,"end":1003},"obj":"Disease"}],"attributes":[{"id":"A595","pred":"tao:has_database_id","subj":"595","obj":"Gene:59272"},{"id":"A596","pred":"tao:has_database_id","subj":"596","obj":"Gene:3569"},{"id":"A597","pred":"tao:has_database_id","subj":"597","obj":"Gene:29110"},{"id":"A598","pred":"tao:has_database_id","subj":"598","obj":"Gene:59272"},{"id":"A599","pred":"tao:has_database_id","subj":"599","obj":"Gene:7124"},{"id":"A600","pred":"tao:has_database_id","subj":"600","obj":"Tax:9606"},{"id":"A601","pred":"tao:has_database_id","subj":"601","obj":"MESH:D012128"},{"id":"A602","pred":"tao:has_database_id","subj":"602","obj":"MESH:D011014"},{"id":"A603","pred":"tao:has_database_id","subj":"603","obj":"MESH:D012128"},{"id":"A604","pred":"tao:has_database_id","subj":"604","obj":"MESH:D060085"},{"id":"A605","pred":"tao:has_database_id","subj":"605","obj":"MESH:D001102"},{"id":"A606","pred":"tao:has_database_id","subj":"606","obj":"MESH:D005334"},{"id":"A607","pred":"tao:has_database_id","subj":"607","obj":"MESH:D001102"},{"id":"A608","pred":"tao:has_database_id","subj":"608","obj":"MESH:D003643"},{"id":"A609","pred":"tao:has_database_id","subj":"609","obj":"MESH:D009181"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"PROS CONS\nChloroquine Anti-viral effect (increase of endosomal pH required for virus/cell fusion, inhibition of toll-like receptor activity, interference with terminal glycosylation of the cellular receptor ACE 2) –\nHydroxychloroquine\nIL-6 inhibitors Treatment of cytokine storm manifestations during ARDS Lack of definite criteria to identify patients to be treated\nPotential community-acquired pneumonia due to immunosuppression\nBaricitinib Interference with viral penetration into the cell by blocking NAK-mediated endocytosis Impairment of IFN anti-viral response\nTreatment of cytokine storm manifestations during ARDS Increased risk of secondary HZV infections\nTNF-inhibitors Interference with viral penetration into the cell Slight increase in viral infection risk\nNSAIDs – Facilitation of viral penetration by overexpression of ACE2\nDelay in diagnosis due to fever masking\nCorticosteroids – Increased risk of viral infection\nIncreased mortality and risk of secondary bacterial or fungal infection"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T71","span":{"begin":53,"end":62},"obj":"Body_part"},{"id":"T72","span":{"begin":85,"end":89},"obj":"Body_part"},{"id":"T73","span":{"begin":264,"end":272},"obj":"Body_part"},{"id":"T74","span":{"begin":488,"end":492},"obj":"Body_part"},{"id":"T75","span":{"begin":581,"end":589},"obj":"Body_part"},{"id":"T76","span":{"begin":726,"end":730},"obj":"Body_part"}],"attributes":[{"id":"A71","pred":"fma_id","subj":"T71","obj":"http://purl.org/sig/ont/fma/fma67180"},{"id":"A72","pred":"fma_id","subj":"T72","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A73","pred":"fma_id","subj":"T73","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A74","pred":"fma_id","subj":"T74","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A75","pred":"fma_id","subj":"T75","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A76","pred":"fma_id","subj":"T76","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"PROS CONS\nChloroquine Anti-viral effect (increase of endosomal pH required for virus/cell fusion, inhibition of toll-like receptor activity, interference with terminal glycosylation of the cellular receptor ACE 2) –\nHydroxychloroquine\nIL-6 inhibitors Treatment of cytokine storm manifestations during ARDS Lack of definite criteria to identify patients to be treated\nPotential community-acquired pneumonia due to immunosuppression\nBaricitinib Interference with viral penetration into the cell by blocking NAK-mediated endocytosis Impairment of IFN anti-viral response\nTreatment of cytokine storm manifestations during ARDS Increased risk of secondary HZV infections\nTNF-inhibitors Interference with viral penetration into the cell Slight increase in viral infection risk\nNSAIDs – Facilitation of viral penetration by overexpression of ACE2\nDelay in diagnosis due to fever masking\nCorticosteroids – Increased risk of viral infection\nIncreased mortality and risk of secondary bacterial or fungal infection"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T231","span":{"begin":301,"end":305},"obj":"Disease"},{"id":"T232","span":{"begin":396,"end":405},"obj":"Disease"},{"id":"T233","span":{"begin":618,"end":622},"obj":"Disease"},{"id":"T234","span":{"begin":655,"end":665},"obj":"Disease"},{"id":"T235","span":{"begin":750,"end":765},"obj":"Disease"},{"id":"T236","span":{"begin":756,"end":765},"obj":"Disease"},{"id":"T237","span":{"begin":916,"end":931},"obj":"Disease"},{"id":"T238","span":{"begin":922,"end":931},"obj":"Disease"},{"id":"T239","span":{"begin":987,"end":1003},"obj":"Disease"},{"id":"T240","span":{"begin":994,"end":1003},"obj":"Disease"}],"attributes":[{"id":"A231","pred":"mondo_id","subj":"T231","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A232","pred":"mondo_id","subj":"T232","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A233","pred":"mondo_id","subj":"T233","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A234","pred":"mondo_id","subj":"T234","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A235","pred":"mondo_id","subj":"T235","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"},{"id":"A236","pred":"mondo_id","subj":"T236","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A237","pred":"mondo_id","subj":"T237","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"},{"id":"A238","pred":"mondo_id","subj":"T238","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A239","pred":"mondo_id","subj":"T239","obj":"http://purl.obolibrary.org/obo/MONDO_0002041"},{"id":"A240","pred":"mondo_id","subj":"T240","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"PROS CONS\nChloroquine Anti-viral effect (increase of endosomal pH required for virus/cell fusion, inhibition of toll-like receptor activity, interference with terminal glycosylation of the cellular receptor ACE 2) –\nHydroxychloroquine\nIL-6 inhibitors Treatment of cytokine storm manifestations during ARDS Lack of definite criteria to identify patients to be treated\nPotential community-acquired pneumonia due to immunosuppression\nBaricitinib Interference with viral penetration into the cell by blocking NAK-mediated endocytosis Impairment of IFN anti-viral response\nTreatment of cytokine storm manifestations during ARDS Increased risk of secondary HZV infections\nTNF-inhibitors Interference with viral penetration into the cell Slight increase in viral infection risk\nNSAIDs – Facilitation of viral penetration by overexpression of ACE2\nDelay in diagnosis due to fever masking\nCorticosteroids – Increased risk of viral infection\nIncreased mortality and risk of secondary bacterial or fungal infection"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T138","span":{"begin":79,"end":84},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T139","span":{"begin":85,"end":89},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T140","span":{"begin":131,"end":139},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T141","span":{"begin":488,"end":492},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T142","span":{"begin":726,"end":730},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"PROS CONS\nChloroquine Anti-viral effect (increase of endosomal pH required for virus/cell fusion, inhibition of toll-like receptor activity, interference with terminal glycosylation of the cellular receptor ACE 2) –\nHydroxychloroquine\nIL-6 inhibitors Treatment of cytokine storm manifestations during ARDS Lack of definite criteria to identify patients to be treated\nPotential community-acquired pneumonia due to immunosuppression\nBaricitinib Interference with viral penetration into the cell by blocking NAK-mediated endocytosis Impairment of IFN anti-viral response\nTreatment of cytokine storm manifestations during ARDS Increased risk of secondary HZV infections\nTNF-inhibitors Interference with viral penetration into the cell Slight increase in viral infection risk\nNSAIDs – Facilitation of viral penetration by overexpression of ACE2\nDelay in diagnosis due to fever masking\nCorticosteroids – Increased risk of viral infection\nIncreased mortality and risk of secondary bacterial or fungal infection"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T157","span":{"begin":10,"end":21},"obj":"Chemical"},{"id":"T158","span":{"begin":235,"end":237},"obj":"Chemical"},{"id":"T160","span":{"begin":240,"end":250},"obj":"Chemical"},{"id":"T161","span":{"begin":670,"end":680},"obj":"Chemical"},{"id":"T162","span":{"begin":771,"end":777},"obj":"Chemical"}],"attributes":[{"id":"A157","pred":"chebi_id","subj":"T157","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A158","pred":"chebi_id","subj":"T158","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A159","pred":"chebi_id","subj":"T158","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A160","pred":"chebi_id","subj":"T160","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A161","pred":"chebi_id","subj":"T161","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A162","pred":"chebi_id","subj":"T162","obj":"http://purl.obolibrary.org/obo/CHEBI_35475"}],"text":"PROS CONS\nChloroquine Anti-viral effect (increase of endosomal pH required for virus/cell fusion, inhibition of toll-like receptor activity, interference with terminal glycosylation of the cellular receptor ACE 2) –\nHydroxychloroquine\nIL-6 inhibitors Treatment of cytokine storm manifestations during ARDS Lack of definite criteria to identify patients to be treated\nPotential community-acquired pneumonia due to immunosuppression\nBaricitinib Interference with viral penetration into the cell by blocking NAK-mediated endocytosis Impairment of IFN anti-viral response\nTreatment of cytokine storm manifestations during ARDS Increased risk of secondary HZV infections\nTNF-inhibitors Interference with viral penetration into the cell Slight increase in viral infection risk\nNSAIDs – Facilitation of viral penetration by overexpression of ACE2\nDelay in diagnosis due to fever masking\nCorticosteroids – Increased risk of viral infection\nIncreased mortality and risk of secondary bacterial or fungal infection"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T27","span":{"begin":85,"end":96},"obj":"http://purl.obolibrary.org/obo/GO_0140253"},{"id":"T28","span":{"begin":85,"end":96},"obj":"http://purl.obolibrary.org/obo/GO_0045026"},{"id":"T29","span":{"begin":85,"end":96},"obj":"http://purl.obolibrary.org/obo/GO_0000768"},{"id":"T30","span":{"begin":85,"end":96},"obj":"http://purl.obolibrary.org/obo/GO_0000747"},{"id":"T31","span":{"begin":122,"end":139},"obj":"http://purl.obolibrary.org/obo/GO_0038024"},{"id":"T32","span":{"begin":159,"end":181},"obj":"http://purl.obolibrary.org/obo/GO_0033578"},{"id":"T33","span":{"begin":168,"end":181},"obj":"http://purl.obolibrary.org/obo/GO_0070085"},{"id":"T34","span":{"begin":461,"end":478},"obj":"http://purl.obolibrary.org/obo/GO_0046718"},{"id":"T35","span":{"begin":518,"end":529},"obj":"http://purl.obolibrary.org/obo/GO_0006897"},{"id":"T36","span":{"begin":699,"end":716},"obj":"http://purl.obolibrary.org/obo/GO_0046718"},{"id":"T37","span":{"begin":750,"end":765},"obj":"http://purl.obolibrary.org/obo/GO_0016032"},{"id":"T38","span":{"begin":796,"end":813},"obj":"http://purl.obolibrary.org/obo/GO_0046718"},{"id":"T39","span":{"begin":916,"end":931},"obj":"http://purl.obolibrary.org/obo/GO_0016032"}],"text":"PROS CONS\nChloroquine Anti-viral effect (increase of endosomal pH required for virus/cell fusion, inhibition of toll-like receptor activity, interference with terminal glycosylation of the cellular receptor ACE 2) –\nHydroxychloroquine\nIL-6 inhibitors Treatment of cytokine storm manifestations during ARDS Lack of definite criteria to identify patients to be treated\nPotential community-acquired pneumonia due to immunosuppression\nBaricitinib Interference with viral penetration into the cell by blocking NAK-mediated endocytosis Impairment of IFN anti-viral response\nTreatment of cytokine storm manifestations during ARDS Increased risk of secondary HZV infections\nTNF-inhibitors Interference with viral penetration into the cell Slight increase in viral infection risk\nNSAIDs – Facilitation of viral penetration by overexpression of ACE2\nDelay in diagnosis due to fever masking\nCorticosteroids – Increased risk of viral infection\nIncreased mortality and risk of secondary bacterial or fungal infection"}

{"project":"LitCovid-sentences","denotations":[{"id":"T105","span":{"begin":0,"end":9},"obj":"Sentence"},{"id":"T106","span":{"begin":10,"end":215},"obj":"Sentence"},{"id":"T107","span":{"begin":216,"end":234},"obj":"Sentence"},{"id":"T108","span":{"begin":235,"end":366},"obj":"Sentence"},{"id":"T109","span":{"begin":367,"end":430},"obj":"Sentence"},{"id":"T110","span":{"begin":431,"end":567},"obj":"Sentence"},{"id":"T111","span":{"begin":568,"end":665},"obj":"Sentence"},{"id":"T112","span":{"begin":666,"end":770},"obj":"Sentence"},{"id":"T113","span":{"begin":771,"end":839},"obj":"Sentence"},{"id":"T114","span":{"begin":840,"end":879},"obj":"Sentence"},{"id":"T115","span":{"begin":880,"end":931},"obj":"Sentence"},{"id":"T116","span":{"begin":932,"end":1003},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"PROS CONS\nChloroquine Anti-viral effect (increase of endosomal pH required for virus/cell fusion, inhibition of toll-like receptor activity, interference with terminal glycosylation of the cellular receptor ACE 2) –\nHydroxychloroquine\nIL-6 inhibitors Treatment of cytokine storm manifestations during ARDS Lack of definite criteria to identify patients to be treated\nPotential community-acquired pneumonia due to immunosuppression\nBaricitinib Interference with viral penetration into the cell by blocking NAK-mediated endocytosis Impairment of IFN anti-viral response\nTreatment of cytokine storm manifestations during ARDS Increased risk of secondary HZV infections\nTNF-inhibitors Interference with viral penetration into the cell Slight increase in viral infection risk\nNSAIDs – Facilitation of viral penetration by overexpression of ACE2\nDelay in diagnosis due to fever masking\nCorticosteroids – Increased risk of viral infection\nIncreased mortality and risk of secondary bacterial or fungal infection"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T67","span":{"begin":264,"end":278},"obj":"Phenotype"},{"id":"T68","span":{"begin":396,"end":405},"obj":"Phenotype"},{"id":"T69","span":{"begin":581,"end":595},"obj":"Phenotype"},{"id":"T70","span":{"begin":866,"end":871},"obj":"Phenotype"}],"attributes":[{"id":"A67","pred":"hp_id","subj":"T67","obj":"http://purl.obolibrary.org/obo/HP_0033041"},{"id":"A68","pred":"hp_id","subj":"T68","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A69","pred":"hp_id","subj":"T69","obj":"http://purl.obolibrary.org/obo/HP_0033041"},{"id":"A70","pred":"hp_id","subj":"T70","obj":"http://purl.obolibrary.org/obo/HP_0001945"}],"text":"PROS CONS\nChloroquine Anti-viral effect (increase of endosomal pH required for virus/cell fusion, inhibition of toll-like receptor activity, interference with terminal glycosylation of the cellular receptor ACE 2) –\nHydroxychloroquine\nIL-6 inhibitors Treatment of cytokine storm manifestations during ARDS Lack of definite criteria to identify patients to be treated\nPotential community-acquired pneumonia due to immunosuppression\nBaricitinib Interference with viral penetration into the cell by blocking NAK-mediated endocytosis Impairment of IFN anti-viral response\nTreatment of cytokine storm manifestations during ARDS Increased risk of secondary HZV infections\nTNF-inhibitors Interference with viral penetration into the cell Slight increase in viral infection risk\nNSAIDs – Facilitation of viral penetration by overexpression of ACE2\nDelay in diagnosis due to fever masking\nCorticosteroids – Increased risk of viral infection\nIncreased mortality and risk of secondary bacterial or fungal infection"}